Active Filter(s):
Details:
Lysogene will be responsible for the preclinical and clinical development, manufacturing, regulatory activities, and commercialization of the drug candidate, globally. which includes FXS01, a gene therapy candidate for the treatment of Fragile X syndrome.
Lead Product(s): FXS01
Therapeutic Area: Genetic Disease Product Name: FXS01
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lysogene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 11, 2021